A study of supplementation with Curcumin to Diabetics

Supplementation with curcumin versus placebo treatment to lower blood glucose in diabetics: a randomised controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN49723587

Enrollment

100

Registered

2010-06-14

Start date

2009-05-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus Nutritional, Metabolic, Endocrine Non-insulin-dependent diabetes mellitus

Interventions

We determine glucose and insulin with related blood indicators in a hospital. The drug name is Curcumin Qingtang tablet. The dosage given is 2.0 g/60 kg BW/d, equivalent Curcumin 300 mg/kg, take this

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Type 2 diabetes mellitus; the condition of patients are stable 2. Fasting blood glucose greater than or equal to 7.8 mmol/L or postprandial blood glucose greater than or equal to 11.1 mmol/L 3. Aged 18 - 65 years, both male and female

Exclusion criteria

Exclusion criteria: 1. Type I diabetes 2. Pregnant or lactating women, or allergic to the tested samples 3. Have history of liver, kidney, hypertension, mental illness, taking other hypoglycaemics 4. People are uncooperative 5. Have diabetic ketosis, acidosis and infection in recent 3 months 6. Taking correlated medications which could potentially influence the purpose of this study 7. Failing to take drugs or the information is incomplete

Design outcomes

Primary

Measure	Time frame
Amended as of 21/09/2010: 1. Lipids (triglycerides [TG], total cholestrol [TC], low-density liporotein cholesterol [LDL-C], high-density lipoprotein cholesterol [HDL-C]) 2. Free fatty acids (FFAs) 3. Lipoprotein lipase (LPL) 4. Adipocyte fatty acid-binding protein (AFABP) 5. Liver ultrasonography 6. HbA1c 7. Apolipoproteins (ApoA1/ApoB) 8. Triacylglycerol 9. Cholesterol 10. 2-hour post-prandial glucose 11. Homeostasis model assessment - insulin resistance (HOMA-IR) Initial information at time of registration: 1. Glucose 2. Insulin	—

Measure

Time frame

Amended as of 21/09/2010: 1. Lipids (triglycerides [TG], total cholestrol [TC], low-density liporotein cholesterol [LDL-C], high-density lipoprotein cholesterol [HDL-C]) 2. Free fatty acids (FFAs) 3. Lipoprotein lipase (LPL) 4. Adipocyte fatty acid-binding protein (AFABP) 5. Liver ultrasonography 6. HbA1c 7. Apolipoproteins (ApoA1/ApoB) 8. Triacylglycerol 9. Cholesterol 10. 2-hour post-prandial glucose 11. Homeostasis model assessment - insulin resistance (HOMA-IR) Initial information at time of registration: 1. Glucose 2. Insulin

—

Secondary

Measure	Time frame
Amended as of 21/09/2010: 1. Age 2. Body mass index (BMI) 3. Diabetes duration 4. Cigarette use 5. Physical activity level 6. Food Frequency Questionnaire (FFQ) Initial information at time of registration: 1. Red blood cell 2. White blood cell 3. Haemoglobin 4. Total protein 5. Albumin 6. Urea nitrogen 7. Creatinine 8. Alanine transaminase 9. Aspartate transaminase 10. Platelet count 11. Height 12. Weight 13. Waist circumference 14. Hip circumference 15. Blood pressure	—

Measure

Time frame

Amended as of 21/09/2010: 1. Age 2. Body mass index (BMI) 3. Diabetes duration 4. Cigarette use 5. Physical activity level 6. Food Frequency Questionnaire (FFQ) Initial information at time of registration: 1. Red blood cell 2. White blood cell 3. Haemoglobin 4. Total protein 5. Albumin 6. Urea nitrogen 7. Creatinine 8. Alanine transaminase 9. Aspartate transaminase 10. Platelet count 11. Height 12. Weight 13. Waist circumference 14. Hip circumference 15. Blood pressure

—

Countries

China

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026